Skip to content

Real world study of migraine treatment in China

Real world study of migraine treatment in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095462
Enrollment
Unknown
Registered
2025-01-07
Start date
2024-08-27
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

Case series:NA

Sponsors

The First Medical Center of the General Hospital of the People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female participants aged >= 18 years-old 2. Primary diagnosis of migraine according to ICHD-3 3. Migraine attacks present for more than 1 year 4. Rimegepant is prescribed for the acute treatment of migraine by physician 5. Written informed consent must be obtained before participant is enrolled

Exclusion criteria

Exclusion criteria: 1. Severe impairment of speech, vision, memory or cognition, or other factors that affectcommunication and ability to complete questionnaires and follow-up 2. Lack of necessary digital tools to complete questionnaires on a digital platform 3. History of hypersensitivity reaction to Rimegepant or to any of its components 4. Participants with severe hepatic impairment or end-stage renal disease 5. Any situation that the investigator believes may affect the patient's participation in thestudy

Design outcomes

Primary

MeasureTime frame
VAS;The headache begins to ease;Drug Satisfaction Questionnaire;

Countries

Chinese

Contacts

Public ContactYu Shengyuan

The First Medical Center of the General Hospital of the People's Liberation Army

ranyenk@126.com+86 186 1158 5856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026